PRJNA715586
PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients (ODYSSEE)
The purpose of this study was to demonstrate the safety of autologous fecal microbiota transfer (AFMT) in 25 AML patients treated with intensive chemotherapy and antibiotics, and to show its efficacy to restore their gut microbiota (ClinicalTrials.gov number: NCT02928523).